Dr Reddy’s Laboratories is among six manufacturers whose royalty-free voluntary licences with Gilead have been expanded to cover an investigational once-yearly lenacapavir option for HIV prevention. The Dr Reddy’s lenacapavir licence is a manufacturing and access-planning step; it does not mean the once-yearly regimen is approved or available.
Dr Reddy’s lenacapavir licence: key takeaways
- The expanded licence covers investigational once-yearly lenacapavir for pre-exposure prophylaxis, or PrEP.
- It is intended for 120 high-incidence countries, primarily low- and lower-middle-income markets.
- Manufacturing readiness and technology transfer can advance while Phase 3 trials continue.
Gilead said the expanded arrangements apply to Dr Reddy’s, Emcure, Eva Pharma, Ferozsons Laboratories, Hetero and Mylan. The model is designed to prepare generic supply partners before potential regulatory decisions, shortening the gap between a successful development programme and broader access.
What the expanded licence changes
Dr Reddy’s already had a voluntary licence for lenacapavir. The new development extends that framework to the once-yearly investigational formulation for HIV prevention. It allows early work on technology transfer, manufacturing preparation and future supply planning for the licensed territories.
That advance work matters because long-acting medicines can require specialised processes, validation and regulatory filings. Starting preparations before the clinical programme finishes can reduce avoidable delays later. But every future launch remains dependent on successful trials, regulatory reviews and country-level requirements.
Why once-yearly prevention is being planned early
Daily oral PrEP works when taken as directed, but adherence can be difficult. A less frequent option may reduce the number of dosing decisions people must make. Gilead is studying once-yearly lenacapavir in the PURPOSE 365 Phase 3 programme, so effectiveness and safety conclusions must wait for trial results and review by regulators.
The licence covers 120 countries with high HIV incidence, mainly low- and lower-middle-income economies. It is royalty-free, which removes one licensing cost for generic partners, but final affordability will also depend on manufacturing scale, procurement, distribution and health-system funding.
For Dr Reddy’s, the agreement extends its role as a global supplier of affordable medicines. It is different from a conventional commercial launch partnership because much of the immediate work happens before a product can be sold. The relevant capability is execution: transferring technology, validating production and preparing dossiers without overstating the certainty of approval.
The arrangement also spreads future supply preparation across several manufacturers rather than a single production base. That can support resilience, although the release provides no company-level allocation, expected volume, launch date or financial guidance for Dr Reddy’s.
Gilead’s release frames this as early access planning during Phase 3, which makes timing central to the story. The licence gives manufacturers preparation time, but it does not bypass evidence review. PURPOSE 365 must still generate the pharmacokinetic, safety and tolerability data that regulators will assess for the once-yearly formulation.
What the deal does — and does not — signal
| Area | What is confirmed | What is not yet confirmed |
|---|---|---|
| Licence | Expanded to once-yearly investigational PrEP | Commercial launch |
| Geography | 120 licensed countries | Availability in every market |
| Development | Phase 3 programme under way | Trial outcome or approval |
| Supply | Readiness planning can begin | Price, volume or launch date |
Indian companies are increasingly using partnerships to build capabilities before demand materialises. Other recent operational examples include RailTel’s WAVES OTT services order and Caterpillar’s India machine launch.
Frequently asked questions
Is once-yearly lenacapavir approved?
No. The once-yearly prevention regimen is investigational and is being studied in Phase 3.
How many countries are covered?
The expanded voluntary licences cover 120 high-incidence countries, primarily low- and lower-middle-income markets.
Does the agreement guarantee immediate access?
No. Future supply depends on successful development, regulatory approvals, manufacturing and country-level introduction.
Sources
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
